SOAT1 and systemic lupus erythematosus: Substantial evidence backs the role of pathways blocked by baricitinib in the pathogenesis of systemic lupus erythematosus [32], including evidence showed effects on expression of serum cytokines, IFNs responsive genes, and JAK-STAT pathway genes [13,18–20], and positive results of a phase III study (SLE-BRAVE-I), which showed that baricitinib 4 mg plus SOC was superior to placebo in conjunction with SOC in reaching SRI-4 response at week 52 [21].